Publication: Critical Care
Abstract
Polymyxin B is first-line therapy for carbapenem-resistant organism (CRO) nosocomial pneumonia, but clinical data on its pharmacokinetic/pharmacodynamic (PK/PD) relationship for this indication were limited. This real-world prospective study in 105 patients used 295 plasma concentrations to build a population pharmacokinetic model with Phoenix NLME, then used logistic regression and Monte Carlo simulation to identify the PK/PD index most predictive of treatment efficacy. AUC/MIC was identified as the most predictive PK/PD index, with an optimal cutoff of 66.9 in combination therapy, and simulations indicated daily doses of 75-100 mg every 12 hours would achieve target attainment at clinically relevant MIC values. The findings support specific polymyxin B dosing recommendations for CRO pneumonia, with adjunctive inhaled therapy suggested for patients unable to reach target concentrations intravenously.
Author(s): Tang T, Li Y, Xu P, Zhong Y, Yang M, Ma W, Xiang D, Zhang B, Zhou Y
Published: April 28, 2023
Phoenix NLME: Turning PK/PD Into a Dosing Target
Phoenix NLME’s population model identified the specific PK/PD index and cutoff that best predicts treatment success in this real-world pneumonia study. Phoenix NLME can be paired with Modeling Assistant, an AI copilot for model building and PML authoring, as part of a Phoenix platform used by 100% of the top 20 pharma companies.
